Literature DB >> 18353732

Strategies to detect adverse effects of antiepileptic drugs in clinical practice.

M Carreño1, A Gil-Nagel, J C Sánchez, E Elices, J M Serratosa, J Salas-Puig, V Villanueva, J Porcel.   

Abstract

OBJECTIVE: The aim was to study the frequency and types of adverse effects (AEs) in patients treated with antiepileptic drugs (AEDs) according to the strategies used by the neurologist to detect them.
METHOD: This cross-sectional epidemiological study was carried out in standard clinical practice. Two strategies were used to detect AEs: spontaneous reporting by the patient, and a checklist of possible treatment-related adverse reactions completed by the patient.
RESULTS: A total of 579 patients were recruited for the study. Roughly a third (33.7%) reported AEs spontaneously, and 65.2% did so when administered the checklist. The main reason for changing medication was lack of efficacy, but significant side effects were also an important reason for modifying treatment in those patients who reported higher levels of discomfort.
CONCLUSIONS: The use of an active approach is recommended for detection of AEs of AED treatment. AEs appear to have a key effect on the decision to change treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353732     DOI: 10.1016/j.yebeh.2008.02.006

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  9 in total

1.  Patient-Reported Adverse Effects Associated with Combination Antiretroviral Therapy and Coadministered Enzyme-Inducing Antiepileptic Drugs.

Authors:  Melissa A Elafros; Gretchen L Birbeck; Joseph C Gardiner; Omar K Siddiqi; Izukanji Sikazwe; Nigel Paneth; Christopher M Bositis; Jason F Okulicz
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

2.  Do Parkinson's disease patients disclose their adverse events spontaneously?

Authors:  Santiago Perez-Lloret; María Verónica Rey; Nelly Fabre; Fabienne Ory; Umberto Spampinato; Jean-Louis Montastruc; Olivier Rascol
Journal:  Eur J Clin Pharmacol       Date:  2011-12-29       Impact factor: 2.953

3.  Medication side effects among people with epilepsy taking phenobarbital in Zambia.

Authors:  Melissa A Elafros; Esther Bui; Gretchen L Birbeck
Journal:  Epilepsy Res       Date:  2014-08-30       Impact factor: 3.045

Review 4.  Adverse events of placebo-treated, drug-resistant, focal epileptic patients in randomized controlled trials: a systematic review.

Authors:  Gaetano Zaccara; Fabio Giovannelli; Massimo Cincotta; Giulia Loiacono; Alberto Verrotti
Journal:  J Neurol       Date:  2014-06-11       Impact factor: 4.849

5.  Adverse Events of Antiepileptic Drugs Using Indonesian Version of Liverpool Adverse Events Profile.

Authors:  Astri Budikayanti; Lubna Muhammad Qadri; Zakiah Syeban; Luh Ari Indrawati; Fitri Octaviana
Journal:  Neurol Res Int       Date:  2018-11-25

6.  Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications.

Authors:  Murtuza Bharmal; Krista Payne; Mark J Atkinson; Marie-Pierre Desrosiers; Donald E Morisky; Eric Gemmen
Journal:  Health Qual Life Outcomes       Date:  2009-04-27       Impact factor: 3.186

Review 7.  Eliciting adverse effects data from participants in clinical trials.

Authors:  Elizabeth N Allen; Clare Ir Chandler; Nyaradzo Mandimika; Cordelia Leisegang; Karen Barnes
Journal:  Cochrane Database Syst Rev       Date:  2018-01-16

8.  Pattern of adverse events of antiepileptic drugs: results of the aESCAPE study in Poland.

Authors:  Barbara Chmielewska; Krystyna Lis; Konrad Rejdak; Marcin Balcerzak; Barbara Steinborn
Journal:  Arch Med Sci       Date:  2013-11-05       Impact factor: 3.318

9.  Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients' Perspectives.

Authors:  Laurent M Willems; Felix Rosenow; Susanne Schubert-Bast; Gerhard Kurlemann; Johann Philipp Zöllner; Thomas Bast; Astrid Bertsche; Ulrich Bettendorf; Daniel Ebrahimi-Fakhari; Janina Grau; Andreas Hahn; Hans Hartmann; Christoph Hertzberg; Frauke Hornemann; Ilka Immisch; Julia Jacobs; Karl Martin Klein; Kerstin A Klotz; Gerhard Kluger; Susanne Knake; Markus Knuf; Klaus Marquard; Thomas Mayer; Sascha Meyer; Hiltrud Muhle; Karen Müller-Schlüter; Felix von Podewils; Susanne Ruf; Matthias Sauter; Hannah Schäfer; Jan-Ulrich Schlump; Steffen Syrbe; Charlotte Thiels; Regina Trollmann; Adelheid Wiemer-Kruel; Bernd Wilken; Bianca Zukunft; Adam Strzelczyk
Journal:  CNS Drugs       Date:  2021-07-17       Impact factor: 5.749

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.